Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05629221
Other study ID # Telemechron - A765
Secondary ID NET-2018-1236720
Status Recruiting
Phase N/A
First received
Last updated
Start date December 30, 2022
Est. completion date September 2024

Study information

Verified date July 2023
Source Azienda Provinciale per i Servizi Sanitari, Provincia Autonoma di Trento
Contact Alexia Giovanazzi
Phone +39 0464403398
Email alexia.giovanazzi@apss.tn.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this randomised trial is to evaluate the impact of using a digital platform called "TreC Diabete" embedded into a novel organizational asset for poorly controlled type 2 diabetes individuals in the Autonomous Province of Trento (PAT). The main question aims to answer whether individuals using the "TreC Diabete" platform will improve their haemoglobin glycated level (Hb1Ac) at 12-month post-randomisation. Participants will be asked to perform some tasks and to share their data with the healthcare staff members through the platform. Control group will receive standard care.


Description:

Type 2 diabetes mellitus (T2DM) is a non-communicable disease representing one of the most serious public health challenges of the 21st century. Its incidence continues to rise in both developed and developing countries, causing the death of 1.5 million people every year. The use of technology (e.g. Smartphone application - App) in the health field has progressively increased as it has been proved effective in helping some individuals manage their long-term diseases. Therefore, it has the potential to reduce health service utilization and its related costs. The objective of this study is to evaluate the impact of using a digital platform called "TreC Diabete" embedded into a novel organizational asset targeting poorly controlled T2DM individuals in the Autonomous Province of Trento (PAT), Italy.This trial was designed as a multi-center, open-label, randomised, superiority study with two parallel-groups and a 1:1 allocation ratio. Individuals regularly attending outpatients diabetes clinics, providing informed consent are randomised to be prescribed TreC Diabete platform or not as part of their personalised care plan. Healthcare staff members will remotely assess the data shared by the participants through the App by using a dedicated online medical dashboard. The primary end-point is the evaluation of the Hb1Ac level at 12-month post-randomisation. Data will be analysed on an intention-to-treat (ITT) basis.This trial is the first conducted in the PAT for the use of an App specifically designed for individuals with poorly controlled T2DM. If the effects of introducing this specific App within a new organizational asset are positive, the digital platform will represent a possible way for people diagnosed with T2DM to better manage their health in the future. Results will be disseminated through conferences and peer-reviewed journals once the study is completed.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date September 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - being diagnosed with T2DM; - aged = 18 and = 85 years old; - having an HbA1c level >7% (53 mmol/mol) and <12% (108 mmol/mol); - being able to walk without walking aids; - having provided written informed consent; - having a smartphone or a tablet and being able to download the App that will be used to insert the required data. Exclusion Criteria: - having a BMI <18 Kg/m² and >45 Kg/m²; - having a sBP <100 or >200 mmHg and/or dBP <50 or >120 mmHg; - being diagnosed with a stage 5 CKD* - being diagnosed with a NYHA stage IV; - poor collaboration (ie unwilling to modify the actual plan of control and therapy, even if not ideal) for which adherence to the study is unlikely - having no possibility of using a smartphone or a tablet - having medical conditions affecting the study participation (i.e. life expectancy < 1 year)

Study Design


Intervention

Other:
TreC Diabete App
Participants can download the App from Google Play or Apple Store and activate the App as soon as the clinician provides them a unique activation code, created through an online medical dashboard. The dashboard allows the interaction between healthcare staff and the participant through the use of a chat or a video-chat. Participants are asked to register some information in the App at set times (e.g. blood pressure). Reminders are periodically sent to remember the participants to perform some tasks. Clinicians will periodically check the information entered by the participant (min frequency 45 days).

Locations

Country Name City State
Italy Azienda Provinciale per i Servizi Sanitari Trento Trentino-Alto Adige

Sponsors (5)

Lead Sponsor Collaborator
Azienda Provinciale per i Servizi Sanitari, Provincia Autonoma di Trento Fondazione Bruno Kessler, Ministero della Salute, Italy, Provincia Autonoma di Trento, TrentinoSalute4.0

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Haemoglobin glycated (Hb1Ac) mean changes Difference in the participants' HbA1c level between the two arms. Blood test carried out by qualified nurses and processes by the local analysis laboratory. Blood tests results are automatically registered on the Hospital Information System (HIS) and reviewed by clinicians and research staff involved in the study. 12 months
Secondary Proportion of participants with Hb1Ac <53mmol/mol Proportion of participants with Hb1Ac <53mmol/mol within the two arms 12 months
Secondary Hb1Ac mean changes Difference in the participants' HbA1c level at different time frame other than at 12 months 3 months, 6 months and 9 months
Secondary Number of hypoglycemic episodes Frequency of hypoglycemic episodes within the two arms 12 months
Secondary Number of subjects reaching targeted lipid profile Proportion of participants reaching the targeted lipid profile (LDL level <70 mg/dl and non-HDL cholesterol level <100 mg/dl) 12 months
Secondary Number of subjects reaching targeted blood pressure levels Proportion of participants reaching the targeted BP levels (sBP <130mmHg or <140 if =65 years old) and dBP <80mmHg) 3 months, 6 months, 9 months, 12 months
Secondary Effect on weight Effect on weight for the app users 3 months, 6 months, 9 months and 12 months
Secondary Level of physical activity Information collected through specific questionnaires 3 months, 6 months, 9 months and 12 months
Secondary Quality of life score changes Changes in quality of life scores for participants of both arms through a specific questionnaire 12 months
Secondary Satisfaction and usability score of the App Satisfaction and usability score of the App in the intervention group only 12 months
Secondary Number of telemedicine visits between participants and nurses/clinicians and chat interactions Process indicator outcome 3 months, 6 months, 9 months and 12 months
Secondary Number of (tele)specialist consultations Process indicator outcome 3 months, 6 months, 9 months and 12 months
Secondary Number of changes in the therapeutic plan Process indicator outcome: number of changes in the therapeutic plan (e.g. drug prescription and dosage) 3 months, 6 months, 9 months and 12 months
Secondary Time spent for telemedicine visits Process indicator outcome: amount of time spent for telemedicine visits (calculated on the basis of the average time spent to deliver eight consecutive nursing visits and eight consecutive medical visits) 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Not yet recruiting NCT06327711 - Benefits of Nutritional Ingredients for Type 2 Diabetes N/A
Recruiting NCT04164602 - The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly
Completed NCT05915338 - Training on Using ıInsulin in Patients With Type 2 Diabetes
Not yet recruiting NCT04998461 - Impact of Obesity, Chronic Kidney Disease and Type 2 Diabetes on Human Urinary Stem Cells
Not yet recruiting NCT04880005 - Digital Individualized and Collaborative Treatment of T2D in General Practice Based on Decision Aid N/A
Recruiting NCT05365529 - Time-Restricted Eating for Type II Diabetes: TRE-T2D N/A
Recruiting NCT03958591 - Effects of Short-term Intensive De-escalation Therapy on Long-term Regimen Simplification Phase 4
Completed NCT05284071 - Actiste® Diabetes Management as a Service (ADMS) Clinical Investigation N/A
Recruiting NCT05501093 - Diabetes Reversal and the Subgingival Microbiota
Active, not recruiting NCT05784220 - The Canadian Diabetes Prevention Program N/A
Active, not recruiting NCT04286555 - Dietary Approaches to Stop Hypertension for Diabetes N/A
Completed NCT05076656 - Epigenetic and Microbiota Modifications Early Phase 1
Completed NCT04423302 - Effect of Totum-63 on Glucose and Lipid Homeostasis in Subjects With Dysglycemia (REVERSE-IT) N/A
Completed NCT05928637 - A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of D745, D759, and D150 Phase 1
Active, not recruiting NCT04660630 - A Real World Research: Comparison of Precision and Experience Therapy for Hypertension, Diabetes or Hyperlipidemias N/A
Recruiting NCT03435328 - Hyposalivation Response To Transcutaneous Electrical Nerve Stimulation In Diabetic Type 2 Patients N/A
Recruiting NCT04447859 - 16-week Flexible vs. 8-week Semaglutide Titration Phase 3
Not yet recruiting NCT03968354 - NASH and Type 2 Diabetes: Role of the Receptor Activator of Nuclear Factor-κB (RANK) and Its Ligand (RANKL)
Terminated NCT04819256 - Primary Care Based Integrated Community Care Team Intervention N/A